KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Share-based Compensation (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Share-based Compensation for 16 consecutive years, with $16.6 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 44.57% to $16.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.6 million through Dec 2025, up 18.85% year-over-year, with the annual reading at $51.6 million for FY2025, 18.85% up from the prior year.
  • Share-based Compensation for Q4 2025 was $16.6 million at Halozyme Therapeutics, up from $12.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $16.6 million in Q4 2025, with the low at $4.7 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $8.8 million, with a median of $9.4 million recorded in 2023.
  • The sharpest move saw Share-based Compensation decreased 3.68% in 2022, then soared 70.75% in 2023.
  • Over 5 years, Share-based Compensation stood at $5.1 million in 2021, then skyrocketed by 40.91% to $7.2 million in 2022, then surged by 33.79% to $9.7 million in 2023, then rose by 18.61% to $11.5 million in 2024, then surged by 44.57% to $16.6 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $16.6 million, $12.2 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.